Antibody Humanization

Area of Science:

• Biotechnology
• Immunology
• Protein Engineering

Background:

• Antibodies from animal species, typically murine, can trigger adverse immune reactions when administered to humans.
• Developing therapeutic antibodies requires minimizing immunogenicity to ensure patient safety and treatment efficacy.

Purpose of the Study:

• To describe the process of antibody humanization for therapeutic applications.
• To explain methods for engineering animal antibodies to reduce immunogenicity in humans.

Main Methods:

• Selecting appropriate human antibody sequences as acceptor templates.
• Identifying critical murine amino acids, including CDRs and framework residues, for retention to preserve antigen binding.
• Optimizing physicochemical properties of the antibody during the humanization process.

Main Results:

• Engineered antibodies exhibit reduced immunogenicity compared to original animal antibodies.
• Preservation of antigen-binding affinity is achieved through strategic amino acid selection.
• Improved antibody characteristics enhance suitability for clinical applications.

Conclusions:

• Antibody humanization is a crucial technique for developing safe and effective antibody-based therapeutics.
• The described methods allow for the successful modification of animal antibodies into human-like structures.
• Careful consideration of structural and physicochemical factors is essential for successful antibody humanization.